In multiple cardiovascular outcome trials, GLP-1 RAs showed a reduction of up to 14% in major adverse cardiovascular events (MACE) and 10% to 11% reduction in hospitalizations for heart failure [7]. The gene discussed is GCG; the disease is heart failure.